WO1999031136A3 - Methods for maintaining or restoring tissue-appropriate phenotype of soft tissue cells - Google Patents

Methods for maintaining or restoring tissue-appropriate phenotype of soft tissue cells Download PDF

Info

Publication number
WO1999031136A3
WO1999031136A3 PCT/US1998/026788 US9826788W WO9931136A3 WO 1999031136 A3 WO1999031136 A3 WO 1999031136A3 US 9826788 W US9826788 W US 9826788W WO 9931136 A3 WO9931136 A3 WO 9931136A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
maintaining
restoring
tissue
soft tissue
Prior art date
Application number
PCT/US1998/026788
Other languages
French (fr)
Other versions
WO1999031136A2 (en
Inventor
Kuber T Sampath
Charles M Cohen
Eiichi Oeda
Kohei Miyazono
Masahiro Kawabata
Original Assignee
Creative Biomolecules Inc
Kuber T Sampath
Charles M Cohen
Eiichi Oeda
Kohei Miyazono
Masahiro Kawabata
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creative Biomolecules Inc, Kuber T Sampath, Charles M Cohen, Eiichi Oeda, Kohei Miyazono, Masahiro Kawabata filed Critical Creative Biomolecules Inc
Priority to JP2000539059A priority Critical patent/JP2002508173A/en
Priority to AU19218/99A priority patent/AU763488B2/en
Priority to CA002314821A priority patent/CA2314821A1/en
Priority to EP98964007A priority patent/EP1040126A2/en
Publication of WO1999031136A2 publication Critical patent/WO1999031136A2/en
Publication of WO1999031136A3 publication Critical patent/WO1999031136A3/en
Priority to AU2003257871A priority patent/AU2003257871A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

Methods for maintaining or restoring tissue-appropriate phenotype of diseased, damaged, or aged mammalian soft tissue cells and methods for treating disorder characterized by a decreased level of endogenous expression of a morphogen. The methods of the invention serve to manipulate any one or several aspects of morphogen-activated regulatory pathways of phenotype-specific protein expression.
PCT/US1998/026788 1997-12-17 1998-12-16 Methods for maintaining or restoring tissue-appropriate phenotype of soft tissue cells WO1999031136A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2000539059A JP2002508173A (en) 1997-12-17 1998-12-16 A method for maintaining or restoring a phenotype appropriate for a tissue of soft tissue cells.
AU19218/99A AU763488B2 (en) 1997-12-17 1998-12-16 Methods for maintaining or restoring tissue-appropriate phenotype of soft tissue cells
CA002314821A CA2314821A1 (en) 1997-12-17 1998-12-16 Methods for maintaining or restoring tissue-appropriate phenotype of soft tissue cells
EP98964007A EP1040126A2 (en) 1997-12-17 1998-12-16 Methods for maintaining or restoring tissue-appropriate phenotype of soft tissue cells
AU2003257871A AU2003257871A1 (en) 1997-12-17 2003-10-24 Methods for maintaining or restoring tissue-appropriate phenotype of soft tissue cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6993197P 1997-12-17 1997-12-17
US11049898P 1998-12-01 1998-12-01
US60/069,931 1998-12-01
US60/110,498 1998-12-01

Publications (2)

Publication Number Publication Date
WO1999031136A2 WO1999031136A2 (en) 1999-06-24
WO1999031136A3 true WO1999031136A3 (en) 1999-08-26

Family

ID=26750579

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/026788 WO1999031136A2 (en) 1997-12-17 1998-12-16 Methods for maintaining or restoring tissue-appropriate phenotype of soft tissue cells

Country Status (5)

Country Link
EP (1) EP1040126A2 (en)
JP (1) JP2002508173A (en)
AU (2) AU763488B2 (en)
CA (1) CA2314821A1 (en)
WO (1) WO1999031136A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE41286E1 (en) 1997-08-14 2010-04-27 Zimmer Orthobiologics, Inc. Compositions for regeneration and repair of cartilage lesions

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6992066B2 (en) 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
US7087577B2 (en) 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
US20020173453A1 (en) * 2000-12-15 2002-11-21 Rama Akella Method of treating renal injury
US7232802B2 (en) 2001-12-21 2007-06-19 Zimmer Orthobiologics, Inc. Compositions and methods for promoting myocardial and peripheral angiogenesis
CN114470162B (en) * 2022-01-28 2023-02-03 浙江大学 Application of GDF6 and over-expression reagent thereof in preparation of myocardial cell protective agent

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033502A1 (en) * 1994-06-03 1995-12-14 Creative Biomolecules, Inc. Manufacture of autogenous replacement body parts
WO1996026737A1 (en) * 1995-03-01 1996-09-06 Creative Biomolecules, Inc. Morphogen-induced dentine regeneration
US5674844A (en) * 1991-03-11 1997-10-07 Creative Biomolecules, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674844A (en) * 1991-03-11 1997-10-07 Creative Biomolecules, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
WO1995033502A1 (en) * 1994-06-03 1995-12-14 Creative Biomolecules, Inc. Manufacture of autogenous replacement body parts
WO1996026737A1 (en) * 1995-03-01 1996-09-06 Creative Biomolecules, Inc. Morphogen-induced dentine regeneration

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ABDOLLAH S ET AL: "TbetaRI Phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 44, no. 272, 31 October 1997 (1997-10-31), pages 27678 27685, XP002077770 *
DE CAESTECKER M P ET AL: "Characterization of functional domains within Smad4/DPC4", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 21, 23 May 1997 (1997-05-23), pages 13690 - 13696, XP002084021 *
DE WINTER J P ET AL: "DPC4 (SMAD4) mediates transforming growth factor-beta1 (TGF-beta1) induced growth inhibition and transcriptional response in breast tumour cells", ONCOGENE, vol. 14, no. 16, 24 April 1997 (1997-04-24), pages 1891 - 1899, XP002084008 *
IMAMURA T. ET AL.: "Smad6 inhibits signalling by the TGF-beta superfamily", NATURE, vol. 389, no. 6651, 9 October 1997 (1997-10-09), LONDON GB, pages 622 - 626, XP002078127 *
KRETZSCHMAR M ET AL: "The TGF-beta family mediator Smad1 is phosphorylated directly and activated by the BMP receptor kinase", GENES AND DEVELOPMENT, vol. 8, no. 11, 15 April 1997 (1997-04-15), pages 984 995, XP002077773 *
LAGNA G ET AL: "Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways", NATURE, no. 383, 31 October 1996 (1996-10-31), pages 832 836, XP002077768 *
LIU F ET AL: "DUAL ROLE OF THE SMAD4/DPC4 TUMOR SUPPRESSOR IN TGFBETA-INDUCIBLE TRANSCRIPTIONAL COMPLEXES", GENES AND DEVELOPMENT, vol. 11, no. 23, 1 December 1997 (1997-12-01), pages 3157 - 3167, XP002911937 *
SOUCHELNYTSKYI S ET AL: "Phosphorylation of Ser-465 and Ser-467 in the C-terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signalling", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 44, no. 272, 31 October 1997 (1997-10-31), pages 28107 28115, XP002077769 *
WRANA J AND ATTISANO L: "MAD-related proteins in TGF-beta signalling", TRENDS IN GENETICS, vol. 12, no. 12, 1 December 1996 (1996-12-01), pages 493 496, XP002077771 *
ZHANG Y ET AL: "THE TUMOR SUPPRESSOR SMAD4/DPC 4 AS A CENTRAL MEDIATOR OF SMAD FUNCTION", CURRENT BIOLOGY, vol. 7, no. 4, 1 April 1997 (1997-04-01), pages 270 - 276, XP002070781 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE41286E1 (en) 1997-08-14 2010-04-27 Zimmer Orthobiologics, Inc. Compositions for regeneration and repair of cartilage lesions

Also Published As

Publication number Publication date
EP1040126A2 (en) 2000-10-04
CA2314821A1 (en) 1999-06-24
WO1999031136A2 (en) 1999-06-24
AU2003257871A1 (en) 2003-11-20
JP2002508173A (en) 2002-03-19
AU1921899A (en) 1999-07-05
AU763488B2 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
CY2436B1 (en) Medicament for treating cardiac inflammatory disease.
NO20045602L (en) Procedure for treating or preventing a vessel system
AU4655296A (en) Compositions and methods for treating tumor cells
ITTO950104A0 (en) CATHETER, PARTICULARLY FOR THE TREATMENT OF CARDIAC ARHYTHMIAS.
HK1046365A1 (en) Lipoxin a4 and analogues for the treatment of dry eye
WO1998020880A3 (en) 11-Halo prostaglandins for the treatment of glaucoma or ocular hypertension
ATE239474T1 (en) USES OF LEVOBUPIVACAIN
AU6186298A (en) Methods and systems for correction of hyperopia and/or astigmatism using ablative radiation
NO994165L (en) Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, travel sickness and dizziness
PL346246A1 (en) Modulating multiple lineage kinase proteins
DE69434777D1 (en) Use of relaxin for the preparation of therapeutic agents
IT1290781B1 (en) ACTIVE THERAPEUTIC AGENT FOR THE TREATMENT OF NEURONAL DEGENERATIVE DISEASES.
WO1999031136A3 (en) Methods for maintaining or restoring tissue-appropriate phenotype of soft tissue cells
BR9811014A (en) "concentrated gene regulatory region specifically for early seed"
WO1998010085A3 (en) Gene therapy for congestive heart failure
EP0369216A3 (en) Pharmaceutical preparation based on ester derivatives of hecogenine, and their use in treating benign prostatic hyperplasia
AU6028898A (en) Methods for cultivating cells and propagating viruses
EP1039883A4 (en) Methods for the treatment of apolipoprotein e related diseases
NO984160L (en) Procedure for the treatment or prevention of interstitial cystitis
HK1002284A1 (en) Novel implant and novel vector for the treatment of acquired diseases
ITTO950099A0 (en) CATHETER, PARTICULARLY FOR THE TREATMENT OF CARDIAC ARHYTHMIAS.
AU5026600A (en) Methods of regulating the condition of mammalian keratinous tissue
DE68911509T2 (en) 26-AMINOCHOLESTEROL AND DERIVATIVES AND ANALOGS THEREOF IN REGULATING CHOLESTEROL accumulation in the body vessels.
AU6144498A (en) P21cip1 or p27kip1 effects on the regulation of differentiation of human mesenchymal stem cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2314821

Country of ref document: CA

Ref country code: CA

Ref document number: 2314821

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 539059

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 19218/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998964007

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998964007

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 19218/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998964007

Country of ref document: EP